ADMA Biologics (ADMA) Gets a Buy Rating from Maxim Group

By Ryan Adsit

Maxim Group analyst Jason McCarthy assigned a Buy rating to ADMA Biologics (ADMAResearch Report) today and set a price target of $6.00. The company’s shares closed last Friday at $2.84.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 11.0% and a 45.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Interpace Diagnostics Group, and SELLAS Life Sciences Group.

Currently, the analyst consensus on ADMA Biologics is a Strong Buy with an average price target of $8.33, a 184.3% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.48 and a one-year low of $1.45. Currently, ADMA Biologics has an average volume of 2.93M.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADMA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ADMA Biologics, Inc. operates as a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.